. In addition, Dr. Zang received a warning letter from the FDA in March 0000 relating to the lack of IND approval before the initiation of a clinical research study in human subjects. For details, please see "Item 0. Directors, Senior Management and Employees - A. Directors and Senior Management - Certain Past Incidents." 